Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
Joint Authors
Aubin, François
Piérard, Gérald E.
Humbert, Philippe
Source
Dermatology Research and Practice
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-10-23
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Malignant melanoma (MM) is one of the most aggressive skin cancer.
The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far.
Immunotherapy is another targeted option.
Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity.
Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased.
The immuno-related adverse effects may be severe and life threatening.
American Psychological Association (APA)
Piérard, Gérald E.& Aubin, François& Humbert, Philippe. 2011. Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?. Dermatology Research and Practice،Vol. 2012, no. 2012, pp.1-4.
https://search.emarefa.net/detail/BIM-452484
Modern Language Association (MLA)
Piérard, Gérald E.…[et al.]. Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?. Dermatology Research and Practice No. 2012 (2012), pp.1-4.
https://search.emarefa.net/detail/BIM-452484
American Medical Association (AMA)
Piérard, Gérald E.& Aubin, François& Humbert, Philippe. Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?. Dermatology Research and Practice. 2011. Vol. 2012, no. 2012, pp.1-4.
https://search.emarefa.net/detail/BIM-452484
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-452484
